Neovasc Inc. NVCN

Healthcare Medical Instruments & Supplies

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.

NDAQ:NVCN - Post by User

Neovasc Inc. > Thomson Reuters Report

<< Previous

Bullboard Posts

Next >>

Comment by Barewoodon Apr 25, 2018 2:28pm

121 Views

Post# 27939549

RE:RE:RE:RE:RE:RE:RE:RE:RE:Thomson Reuters Report

Sanderz wrote:

Barewood wrote:

Barewood wrote: That's not to bad. Have you averaged down at all? At this price it wouldn't take much to get you down to .06.

Based on 575000 shares you would have had to paid $60,375 plus fees. At this point, for every penny you average down would cost you $10,000.00, so you need approx 40k to get you to .06.

Yeah, 40k, that's not going to happen lol.

But, I did make an error, I was in originally at 10 or 10.5 cents (can't quite remember), and I did average down once. so I'm actually down to 8 cents. but, frig, the SP hardly can get past 6.5 lately!

I'm really confident that this will begin to move once we get our update on our progress. I do believe our CEO Fred Colen has his sh*t together. To bad Neovasc didn't have him from the beginning. The first QTR results are due May 09 and it is probable our progress report will be included if not sooner.

<< Previous

Bullboard Posts

Next >>

How this company is transforming the immersive tech industry